Adenosine deaminase gene variant in diabetes and obesity
Tóm tắt
Personal medicine is a new notion for individualizing treatment in the future. Studying pathogenic markers including genetic variants would be beneficial in better diagnosis and management of complex diseases such as diabetes and obesity. Adenosine deaminase (ADA) is a purine metabolic enzyme and modulates insulin activity in various tissues through several different mechanisms. Increased ADA activity is associated with decreased glucose uptake. A significant increase in serum deaminase activity has been reported in patients with T2DM and obesity. ADA gene polymorphisms seem to affect ADA enzymatic activity and a polymorphism at the position 4223 in the first intron of ADA gene (ADA 4223 A/C) has been previously associated with obesity. The aim of this study was to explore ADA gene 4223 A/C polymorphism and its association with obesity in patients with Type 2 diabetes. Obese patients (N = 133: 64 diabetic +69 non-diabetic) with BMI ≥ 30 and subjects with BMI < 30 (N = 152: 83 diabetics +69 non-diabetic) were recruited into a case-control association study. Blood samples were collected and after DNA extraction, the allele and genotype frequency for ADA gene polymorphism was determined using PCR-RFLP technique. We observed a significant increase for the frequency of AA+CA genotype in non-obese patients with diabetes compared to obese patients with diabetes (P = 0.04, OR = 2.1, 95%CI; 0.93–4.9). The higher frequency of AA+CA genotype in none obese diabetes individuals and lower frequency of this genotype in obese diabetes subjects indicates an important role for ADA gene polymorphism in diabetes subjects without obesity.
Tài liệu tham khảo
Liao W-L, Tsai F-J. Personalized medicine in type 2 diabetes. BioMedicine. 2014;4(2)
Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA. 2015;314(10):999–1000.
Bray GA. Treatment for obesity: a nutrient balance/nutrient partition approach. Nutr Rev. 1991;49(2):33–45.
Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin N Am. 2003;32(4):895–914.
Jadhav AA, Jain A. Elevated adenosine deaminase activity in overweightand obese Indian subjects. Arch Physiol Biochem. 2012;118(1):1–5.
Johansson SM, et al. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue—interactions with insulin. Eur J Pharmacol. 2008;597(1–3):92–101.
Khemka VK, et al. Raised serum adenosine deaminase level in nonobese type 2 diabetes mellitus. Sci World J. 2013;2013
Vergauwen L, Hespel P, Richter EA. Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. J Clin Invest. 1994;93(3):974–81.
Figler RA, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes. 2011;60(2):669–79.
Bell GI, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci. 1991;88(4):1484–8.
Kurtul N, et al. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica-Hradec Kralove. 2004;47(1):33–6.
Amoli MM, et al. Adenosine deaminase gene polymorphism is associated with obesity in Iranian population. Obes Res Clin Pract. 2007;1(3):173–7.
Di Pietro F, et al. Genomic DNA extraction from whole blood stored from 15-to 30-years at− 20 C by rapid phenol–chloroform protocol: a useful tool for genetic epidemiology studies. Mol Cell Probes. 2011;25(1):44–8.
Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005;115(6):1431–9.
Albuquerque D, et al. The contribution of genetics and environment to obesity. Br Med Bull. 2017;123(1):159–73.
Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14.
Bowden DW, et al. Identification of genetic markers flanking the locus for maturity-onset diabetes of the young on human chromosome 20. Diabetes. 1992;41(1):88–92.
Mohan V, et al. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217–30.
Vaag A, Lund SS. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention? Appl Physiol Nutr Metab. 2007;32(5):912–20.
Prakash MS, et al. Altered adenosine deaminase activity in type 2 diabetes mellitus. Age. 2006;43(6.2):44–6.
Yang Z, et al. Ultraviolet polarized LiDAR system for biological aerosols. Int J Simul Syst Sci Technol. 2016;17
Christesen SD, et al. Ultraviolet fluorescence lidar detection of bioaerosols. In Atmospheric Propagation and Remote Sensing III. 1994. International Society for Optics and Photonics.
Hoshino T, et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Res Clin Pract. 1994;25(2):97–102.
Vannucci SJ, et al. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochem J. 1992;288(1):325–30.
Takasuga S, et al. Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. J Biol Chem. 1999;274(28):19545–50.
Warrier AC, et al. Evaluation of adenosine deaminase activity and lipid peroxidation levels in diabetes mellitus. Indian J Clin Biochem. 1995;10(1):9.
Zavialov AV, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88(2):279–90.
Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15(11):2792–800.
Elk N, Iwuchukwu OF. Using personalized medicine in the management of diabetes mellitus. Pharmacotherapy: J Human Pharmacol Drug. Therapy. 2017;37(9):1131–49.
Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011;57(2):231–40.
Blakemore AI, Froguel P. Investigation of Mendelian forms of obesity holds out the prospect of personalized medicine. Ann N Y Acad Sci. 2010;1214(1):180–9.
Yaghoubi H, Haghi M, Radjabalizadeh K. Association of adenosine deaminase (ADA) gene 4223A/C polymorphism with obesity in Ardabil, Iran. Pathobiol Res. 2017;20(2):79–87.
Chielle EO, et al. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult. Clin Chem Lab Med (CCLM). 2015;53(7):1041–7.
Takhshid MA, et al. G22A polymorphism of adenosine deaminase and its association with biochemical characteristics of gestational diabetes mellitus in an Iranian population. Iran J Med Sci. 2015;40(2):170.
Chielle EO, et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem. 2016;49(7–8):548–53.